Once the BOD lets the shorts escape, maybe ARNA will be acquired/sold. God forbid ARNA shareholders should make a profit, or shorts lose any cash. Are we waiting for the next useless Jack/Harry, or a deal???
I hate when shorts, using inside info, escape. How do they always know??? How have they covered 20MM shares without the price rising???
agreed, IMGN filled their opening within a month of announcing the CEO was departing. I'll assume they had a head start, but it does not take this long to find good candidates unless the BOD has something to hide and is looking for a CYA candidate, or they are searching for a buyer. If they are searching for a buyer, I would prefer an auction/competitive deal, not a private, uncompetitive deal.
thanks for the details. So unless CVOT is a bust, or there are other safety issues, which is not likely, they would have to pay up to exit. Seems like JL and Spector did at least one thing right.
Just to the opposite of what you would normally do because they own the stock and the large short position, so they totally control the price. Buy low, sell any good news. Eventually it will probably work out for longs, but owning a DF-controlled stock is not fun. IMO based on years of biotech investing and trading experience and watching these bio short hedge fund loan shark "criminals" work.
another tape painting and another day with no word from ARNA management about the CEO. Nice work!
Since my last check (about every 2 weeks) total employment based on Linked-in has declined by 4 to 225 including 1 less director (58) and 1 less VP (17). It's still bloated, but heading in the right direction!
strong call volume, but it appears to be call sales based on the prices. Maybe not if the trades were around the lows, I did not see them real time.
I was told a few weeks ago they were down to 2, but it can take time to finish the process and get the person started. I just hope they hire someone that is not a BOD yes-person and in fact I think the BOD must resign, so the new CEO can start with a clean slate. We need a turnaround specialist with strong go-no go decision making experience, strong M&A, strong partnering, strong clinical trials...no strong in misleading shareholders and sucking up to the BOD.
If they want to get into the FD business GILD would buy them, but if the HepC product don;t work nobody will buy for HepC. Nice action, must be something behind it, some news leak???
at the same time BBEP is down 10% and looking like a dead stock heading to 0. Higher oil prices, at least $50+ and lower costs needed in the next 12-18 months...It's certainly possible.
I'm going to assume JNJ knows more about evaluating pipeline products than anyone here and go with that until prove otherwise.
the closing tape painting algo has been in full force the past few days. Shorts are clearly exiting, slowly but surely. If ARNA could ever get things moving forward in a more rapid pace...where the flippin CEO, so we can decide on 371 partner early, or no do phase II...We need a turnaround and sale person, not a BOD yes person that will continue to milk the shareholders as long as possible. This is getting OLD!!!
if all but 5 had a follow up, it's pretty certain and I would consider any pollyps found to be helpful to the patient. Sounds overall very positive to me, but that does not ensure USPSTF will agree and the test will be widely covered, which is needed to turn the finances around.